Page last updated: 2024-10-23

azasetron and Neoplasms

azasetron has been researched along with Neoplasms in 4 studies

azasetron: a selective 5-HT3 receptor antagonist; structure given in first source;

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"Olanzapine can improve the complete response of delayed nausea and vomiting in patients receiving the highly or moderately emetogenic chemotherapy comparing with the standard therapy of antiemesis, as well as improve the QoL of the cancer patients during chemotherapy administration."9.14Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. ( Chen, J; Liu, J; Liu, X; Tan, L; Yan, Z; Yang, H; Zhang, D, 2009)
"Azasetron, a selective 5-HT3 receptor antagonist, has been previously shown to be highly effective in the prophylaxis of nausea and vomiting induced by anticancer drugs and is widely used in the clinical setting in Japan."9.08[Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP]. ( Akiyama, M; Kimura, E; Niimi, S; Tanaka, T; Watanabe, A, 1996)
"Olanzapine can improve the complete response of delayed nausea and vomiting in patients receiving the highly or moderately emetogenic chemotherapy comparing with the standard therapy of antiemesis, as well as improve the QoL of the cancer patients during chemotherapy administration."5.14Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. ( Chen, J; Liu, J; Liu, X; Tan, L; Yan, Z; Yang, H; Zhang, D, 2009)
"BNT used in coordination with Azasetron for alleviating vomiting could enhance the antiemetic effect, reduce the adverse effects of chemotherapy, such as constipation, abdominal distension and anorexia, and thus to increase the compliance of patients."5.12[Clinical efficacy of Bannaitong Mdicinal Tea combined with azasetron in preventing and treating chemotherapy induced gastrointestinal reaction]. ( Li, GL; Li, YW, 2007)
"Azasetron, a selective 5-HT3 receptor antagonist, has been previously shown to be highly effective in the prophylaxis of nausea and vomiting induced by anticancer drugs and is widely used in the clinical setting in Japan."5.08[Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP]. ( Akiyama, M; Kimura, E; Niimi, S; Tanaka, T; Watanabe, A, 1996)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's3 (75.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tan, L1
Liu, J1
Liu, X1
Chen, J1
Yan, Z1
Yang, H1
Zhang, D1
Li, GL1
Li, YW1
Okuyama, K1
Yoshimoto, K1
Iwase, O1
Ozeki, T1
Yamada, Y1
Kimura, E1
Niimi, S1
Watanabe, A1
Akiyama, M1
Tanaka, T1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting[NCT02970643]48 participants (Anticipated)Interventional2016-07-31Enrolling by invitation
Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent Nausea and Vomiting Induced by Chemotherapy::A Non-inferiority, Prospective, Multi-Centered, Randomized, Controlled, Phase III Clinical Trial[NCT05805800]Phase 3238 participants (Anticipated)Interventional2023-03-15Recruiting
Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting---A Randomized Single Center Phase III Trial[NCT02484911]Phase 3120 participants (Actual)Interventional2015-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Proportion of Participants Receiving HEC With Complete Response in Overall Phase

"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 0 to 120 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen20
Control Regimen15

Proportion of Participants Receiving HEC With Complete Response in the Acute Phase

Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy. (NCT02484911)
Timeframe: 0 to 24 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen20
Control Regimen17

Proportion of Participants Receiving HEC With Complete Response in the Delayed Phase

"Delayed phase was defined as 24 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 24 to 120 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen20
Aprepitant Regimen15

Proportion of Participants Receiving HEC With No Vomiting in the Acute Phase

"Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue )" (NCT02484911)
Timeframe: 0 to 24 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen18
Control Regimen15

Proportion of Participants Receiving HEC With No Vomiting in the Delayed Phase

"Overall Phase was defined as 24 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 24 to 120 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen17
Control Regimen7

Proportion of Participants Receiving HEC With No Vomiting in the Overall Phase

"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0 to 120 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen17
Control Regimen6

Proportion of Participants Receiving MEC With Complete Response in Overall Phase

"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 0 to 120 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen36
Control Regimen40

Proportion of Participants Receiving MEC With Complete Response in the Acute Phase

Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy. (NCT02484911)
Timeframe: 0 to 24 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen36
Control Regimen41

Proportion of Participants Receiving MEC With Complete Response in the Delayed Phase

"Delayed phase was defined as 24 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 24 to 120 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen36
Control Regimen40

Proportion of Participants Receiving MEC With No Vomiting in the Acute Phase

"Overall Phase was defined as 0 to 24 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0 to 24 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen35
Control Regimen40

Proportion of Participants Receiving MEC With No Vomiting in the Delayed Phase

"Overall Phase was defined as 24 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 24 to 120 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen30
Control Regimen31

Proportion of Participants Receiving MEC With No Vomiting in the Overall Phase

"Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0-120 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen30
Control Regimen30

Trials

3 trials available for azasetron and Neoplasms

ArticleYear
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
    Journal of experimental & clinical cancer research : CR, 2009, Sep-23, Volume: 28

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc

2009
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
    Journal of experimental & clinical cancer research : CR, 2009, Sep-23, Volume: 28

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc

2009
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
    Journal of experimental & clinical cancer research : CR, 2009, Sep-23, Volume: 28

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc

2009
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
    Journal of experimental & clinical cancer research : CR, 2009, Sep-23, Volume: 28

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc

2009
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
    Journal of experimental & clinical cancer research : CR, 2009, Sep-23, Volume: 28

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc

2009
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
    Journal of experimental & clinical cancer research : CR, 2009, Sep-23, Volume: 28

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc

2009
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
    Journal of experimental & clinical cancer research : CR, 2009, Sep-23, Volume: 28

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc

2009
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
    Journal of experimental & clinical cancer research : CR, 2009, Sep-23, Volume: 28

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc

2009
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
    Journal of experimental & clinical cancer research : CR, 2009, Sep-23, Volume: 28

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc

2009
[Clinical efficacy of Bannaitong Mdicinal Tea combined with azasetron in preventing and treating chemotherapy induced gastrointestinal reaction].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2007, Volume: 27, Issue:10

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, He

2007
[Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:4

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cisplatin;

1996

Other Studies

1 other study available for azasetron and Neoplasms

ArticleYear
[Clinical evaluation of antiemetic effects of 5-hydroxytryptamine receptor type 3 (5HT3 receptor) antagonists based on changes in eating condition in cancer patients receiving chemotherapy].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2008, Volume: 128, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimi

2008